English Abstract
Journal Article
Add like
Add dislike
Add to saved papers

[Prognosis and adjuvant chemotherapy of axillary node-negative breast cancer patients].

The significance of postoperative chemotherapy was studied in 439 cases of unilateral primary breast cancer which were proved histologically with no axillary lymph node metastasis. The survival rate was analyzed by life table method. The prognosis of node negative breast cancer patients was mainly associated with tumor size. 10 year survival rate of patients with tumor less than 3 cm treated operativel and by operation combined with chemotherapy was 92.60% and 94.13% respectively. If tumor size was larger than 3 cm, the ten year survival rate of the patients treated operatived was 79.89%, and that of the patients with combined theropy 96.02%. The prognosis was statistically different between the two groups. As to age, status of menopause, pathologral type, kind of surgery and status of ER, the prognosis of patients treated by combined therapy was better than that of patients treated by operation alone. The postoperative chemotherapy was not significantly beneficial to breast cancer patients with tumor less than 3 cm.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app